Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

PR Newswire 4 days ago

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

PR Newswire 13 days ago

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire November 7, 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

PR Newswire November 5, 2024

Carisma Therapeutics Announces Changes to its Board of Directors

PR Newswire October 30, 2024

Carisma Therapeutics Announces Upcoming Presentations at SITC 2024

PR Newswire October 4, 2024

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

PR Newswire September 10, 2024

Carisma Therapeutics to Present at Upcoming Conferences

PR Newswire September 3, 2024

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire August 8, 2024

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

PR Newswire August 6, 2024

Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

PR Newswire August 6, 2024

Carisma Therapeutics Announces Changes to its Board of Directors

PR Newswire July 1, 2024

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

PR Newswire June 27, 2024

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

PR Newswire June 25, 2024

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

PR Newswire June 25, 2024

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

PR Newswire June 13, 2024

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference

PR Newswire May 30, 2024

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

PR Newswire May 16, 2024

Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire May 9, 2024

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024

PR Newswire May 8, 2024